Literature DB >> 32985799

MMP-7, -8, -9, E-cadherin, and beta-catenin expression in 34 ameloblastoma cases.

Jetta Kelppe1, Hanna Thorén2,3, Caj Haglund4,5, Timo Sorsa6,7, Jaana Hagström1,5,8.   

Abstract

OBJECTIVES: Ameloblastoma is a benign, locally aggressive odontogenic tumor with high recurrence rates. Matrix metalloproteinases (MMPs) mediate extracellular integrity in normal and pathological conditions, and exert multiple functions coordinating inflammation and tumor progression. E-cadherin and beta-catenin are adherence junction molecules in cell-to-cell connections. We investigated the involvement of MMP-7, -8, -9, E-cadherin, and beta-catenin in ameloblastoma and the surrounding extracellular matrix.
MATERIAL AND METHODS: Our material consisted of 30-34 tissue samples from ameloblastoma patients of Helsinki University Hospital. We used immunohistochemistry to detect the expression of the biomarkers. Two oral pathologists independently scored the immunoexpression intensities and statistical calculations were made based on the results.
RESULTS: E-cadherin expression was weaker in the maxillary than in mandibular ameloblastomas. Beta-catenin was expressed in the ameloblastoma cell membranes. We detected MMP-8 and -9 expression in polymorphonuclear neutrophils in the extracellular area and these MMPs correlated positively with each other. Osteoclasts lining bone margins and multinuclear giant cells expressed MMP-9. Neither MMP-8 nor MMP-9 immunoexpression could be detected in ameloblastoma cells. MMP-7 expression was seen in some apoptotic cells.
CONCLUSION: The fact that E-cadherin immunoexpression was weaker in maxillary compared to mandibular ameloblastomas might associate to earlier recurrences. It promotes the idea of mandibular and maxillary ameloblastoma exerting differences in their biologies. We detected MMP-8 and -9 in polymorphonuclear neutrophils which relates to these MMPs participating in extracellular remodeling through a mild inflammatory process. Bone degradation around ameloblastoma may be due to MMP-9 in osteoclasts but this phenomenon might be an independent process and needs further investigations.
© 2020 The Authors. Clinical and Experimental Dental Research published by John Wiley & Sons Ltd.

Entities:  

Keywords:  E-cadherin; MMP-7; MMP-8; MMP-9; ameloblastoma; beta-catenin

Mesh:

Substances:

Year:  2020        PMID: 32985799      PMCID: PMC7853880          DOI: 10.1002/cre2.331

Source DB:  PubMed          Journal:  Clin Exp Dent Res        ISSN: 2057-4347


  29 in total

1.  Matrilysin stimulates DNA synthesis of cultured vascular endothelial cells and induces angiogenesis in vivo.

Authors:  I Nishizuka; Y Ichikawa; T Ishikawa; M Kamiyama; S Hasegawa; N Momiyama; K Miyazaki; H Shimada
Journal:  Cancer Lett       Date:  2001-11-28       Impact factor: 8.679

2.  beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer.

Authors:  T Brabletz; A Jung; S Dag; F Hlubek; T Kirchner
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

3.  Immunohistochemical expression of matrilysins (MMP-7 and MMP-26) in ameloblastomas and adenomatoid odontogenic tumors.

Authors:  Valéria Souza Freitas; Cristina Ruan Ferreira de Araújo; Pollianna Muniz Alves; Lélia Batista de Souza; Hébel Cavalcanti Galvão; Roseana de Almeida Freitas
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2009-07-01

Review 4.  Desmoplastic ameloblastoma - A review.

Authors:  Zhi-Jun Sun; Yan-Ru Wu; Ning Cheng; Roger A Zwahlen; Yi-Fang Zhao
Journal:  Oral Oncol       Date:  2009-07-23       Impact factor: 5.337

5.  Immunohistochemical detection of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in ameloblastomas.

Authors:  Hiroyuki Kumamoto; Kensuke Yamauchi; Mitsuhide Yoshida; Kiyoshi Ooya
Journal:  J Oral Pathol Med       Date:  2003-02       Impact factor: 4.253

6.  Patterns of MMP-2 and MMP-9 expression in human cancer cell lines.

Authors:  M W Roomi; J C Monterrey; T Kalinovsky; M Rath; A Niedzwiecki
Journal:  Oncol Rep       Date:  2009-05       Impact factor: 3.906

7.  Immunoexpression of MMPs-1, -2, and -9 in ameloblastoma and odontogenic adenomatoid tumor.

Authors:  B F Ribeiro; D P P Iglesias; G J F Nascimento; H C Galvão; A M C Medeiros; R A Freitas
Journal:  Oral Dis       Date:  2009-06-10       Impact factor: 3.511

8.  A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells.

Authors:  Thomas L Andersen; Maria del Carmen Ovejero; Tove Kirkegaard; Thomas Lenhard; Niels T Foged; Jean-Marie Delaissé
Journal:  Bone       Date:  2004-11       Impact factor: 4.398

9.  Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression.

Authors:  Antonietta Rosella Farina; Andrew Reay Mackay
Journal:  Cancers (Basel)       Date:  2014-01-27       Impact factor: 6.639

10.  MMP-7, -8, -9, E-cadherin, and beta-catenin expression in 34 ameloblastoma cases.

Authors:  Jetta Kelppe; Hanna Thorén; Caj Haglund; Timo Sorsa; Jaana Hagström
Journal:  Clin Exp Dent Res       Date:  2020-09-28
View more
  3 in total

1.  Bacteroides fragilis Enterotoxin Upregulates Matrix Metalloproteinase-7 Expression through MAPK and AP-1 Activation in Intestinal Epithelial Cells, Leading to Syndecan-2 Release.

Authors:  Jong Ik Jeon; Keun Hwa Lee; Jung Mogg Kim
Journal:  Int J Mol Sci       Date:  2021-10-30       Impact factor: 5.923

2.  Use of ATP-Binding Cassette Subfamily A Member 13 (ABCA13) for Sensitive Detection of Focal Pathological Forms of Subclinical Bovine Paratuberculosis.

Authors:  Cristina Blanco-Vázquez; Marta Alonso-Hearn; Natalia Iglesias; Patricia Vázquez; Ramón A Juste; Joseba M Garrido; Ana Balseiro; María Canive; Javier Amado; Manuel A Queipo; Tania Iglesias; Rosa Casais
Journal:  Front Vet Sci       Date:  2022-03-10

3.  MMP-7, -8, -9, E-cadherin, and beta-catenin expression in 34 ameloblastoma cases.

Authors:  Jetta Kelppe; Hanna Thorén; Caj Haglund; Timo Sorsa; Jaana Hagström
Journal:  Clin Exp Dent Res       Date:  2020-09-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.